Quick Answer
Grace Therapeutics, Inc. reported Stockholders Equity of $66.61 million for fiscal year 2025.
Grace Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $66.61M | +7.9% |
| 2024 | $61.74M | -9.1% |
| 2023 | $67.95M | -37.2% |
| 2022 | $108.27M | +94.5% |
| 2021 | $55.66M | +328.4% |
| 2020 | $12.99M | +17.6% |
| 2019 | $11.04M | +53.6% |
| 2018 | $7.19M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $64.89M | +24.5% | +3.3% |
| September 30, 2025 | $62.82M | +11.9% | -1.2% |
| June 30, 2025 | $63.55M | +7.1% | -4.6% |
| March 31, 2025 | $66.61M | +7.9% | +27.8% |
| December 31, 2024 | $52.14M | -19.4% | -7.1% |
| September 30, 2024 | $56.13M | -15.9% | -5.4% |
| June 30, 2024 | $59.36M | -7.3% | -3.9% |
| March 31, 2024 | $61.74M | -9.1% | -4.5% |
- Grace Therapeutics, Inc. showed an increase of +7.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Grace Therapeutics, Inc.’s stockholders equity has grown by 826.0% (from $7.19 million to $66.61 million).
- The most recent figure is from Grace Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: